Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection
This study is currently recruiting participants.
Verified by HaEmek Medical Center, Israel, February 2008
Sponsored by: HaEmek Medical Center, Israel
Information provided by: HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT00678028
  Purpose

Due to genetic polymorphism about 15%-30% of the world population have low levels of MBL (Mannose Binding Lectin) in serum (below 500ng/mL). Different studies reported correlation between polymorphism in the MBL gene with low levels of MBL in serum and higher frequency of recurrent infections, severity of sepsis, ARDS and other infections. Urinary Tract Infection (UTI) is one of the very common infection in women. Since MBL is part of the innate immunity and there are proofs of relation between patients with recurrent infections and lack of MBL, we decided to explore a possible relation between low levels of MBL and different genotypes of MBL in young women and the risk to develop recurrent UTI.


Condition
Recurrent Urinary Tract Infections

MedlinePlus related topics: Urinary Tract Infections
U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Prospective
Official Title: Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection

Further study details as provided by HaEmek Medical Center, Israel:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

whole blood for genetic test and serum for MBL test


Estimated Enrollment: 200
Study Start Date: February 2008
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

young women with recurrent UTI - study group and young women witout recurrent UTI - a control group

Criteria

Inclusion Criteria:

  • women above 18 years old.
  • premenopausal
  • recurrent UTI

Exclusion Criteria:

  • pregnancy
  • immunocompromised
  • active malignancy
  • HIV carrier
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00678028

Contacts
Contact: Orna Nitzan, MD 972-4-6495132 orna_ni@clalit.org.il
Contact: Raul Raz, M.D. 972-4-6494259 raz_r@clalit.org.il

Locations
Israel
Ha'Emek Medical Center Recruiting
Afula, Israel, 18101
Contact: Orna Nitzan, MD     972-4-6495132     orna_ni@clalit.org.il    
Contact: Raul Raz, M.D.     972-4-6494259     raz_r@clalit.org.il    
Principal Investigator: Orna Nitzan, MD            
Sub-Investigator: Raul Raz, MD            
Sub-Investigator: Bibiana Chazan, MD            
Sub-Investigator: Yasir Hujeirat, PhD            
Sub-Investigator: Raul Colodner, PhD            
Sponsors and Collaborators
HaEmek Medical Center, Israel
  More Information

Responsible Party: Ha'emek Medical Center, Afula, Israel ( Dr. Orna Nitzan )
Study ID Numbers: 0080-07-EMC
Study First Received: February 17, 2008
Last Updated: May 14, 2008
ClinicalTrials.gov Identifier: NCT00678028  
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by HaEmek Medical Center, Israel:
MBL, UTI

Study placed in the following topic categories:
Urologic Diseases
Urinary Tract Infections
Recurrence

Additional relevant MeSH terms:
Communicable Diseases
Infection

ClinicalTrials.gov processed this record on January 15, 2009